List view / Grid view
25 November 2014 | By Promethera Biosciences
Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital...
25 November 2014 | By Braun
Nationwide consumer survey sponsored by Braun discovers that regular blood pressure measurement must become a higher priority...
25 November 2014 | By Roche
Roche is increasing the payroll for its workforce of over 13,000 in Switzerland by 1.4 percent with effect from 1 April 2015...
25 November 2014 | By Frost & Sullivan
Frost & Sullivan profiles key medical device manufacturers in the region, where the market is expected to grow at a CAGR of 3.1 percent between 2014 and 2018...
24 November 2014 | By Bioquell
The Bioquell wound treatment system, BioxyQuell, has been tested at a wound care clinic in Hampshire with patients suffering from long term chronic venous leg ulceration. The results, presented in two case studies, show how aqueous oxygen peroxide (AOP) applied using the BioxyQuell system reduced odours and pain as well…
24 November 2014 | By Lucideon
Lucideon, the international provider of materials development, testing and assurance, has launched a new Composites Information Service.
24 November 2014 | By Doctors of the World UK
Doctors of the World UK is to run a 100-bed Ebola treatment centre in Sierra Leone that’s being custom-built in a town called Moyamba...
24 November 2014 | By Enanta Pharmaceuticals, Inc.
Enanta announces CHMP positive opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the treatment of chronic hepatitis C in Europe...
24 November 2014 | By BioM Biotech Cluster Development GmbH
Munich is the top location for biotechnology and pharmaceutical industries according to a new study by the Chamber of Industry and Commerce (IHK)...
24 November 2014 | By Celgene International Sàrl
Celgene receives positive CHMP opinion for OTEZLA® (apremilast), the first oral PDE4 inhibitor for the treatment of patients with psoriasis and psoriatic arthritis...
21 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
21 November 2014 | By STALLERGENES / ActoGeniX
STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments...
21 November 2014 | By GlobalData
The vote against the recommendation that the US Food and Drug Administration (FDA) approves Novartis’ panobinostat (Farydak) for use in relapsed/refractory multiple myeloma by the Oncologic Drugs Advisory Committee (ODAC) signals that a US marketing authorization is unlikely to be granted, according to an analyst with research and consulting firm…
20 November 2014 | By Medical Research Council
Life-saving measures for patients have moved a step closer following the announcement by Prime Minister David Cameron of investments totalling over £30 million in emerging new treatments and technologies...
20 November 2014 | By Moberg Pharma
Moberg Pharma AB have appointed Jeff Vernimb as General Manager for its U.S. operations and a member of Moberg’s Management Team – effective from December 15, 2014...
